When the scale stalls but your composition shifts, you'll know it's progress
Sitagliptin, a dipeptidyl peptidase-4 inhibitor, was selected as an active-comparator placebo proxy because it was recommended in clinical guidelines as a second-line glucose-lowering therapy, had a similar high cost to the study drugs, showed no effect on cardiovascular outcomes in a large randomized controlled trial and has been validated as a placebo proxy in prior claims-based research 20,41
Cellular energy Speaking of personal bests, research suggests that carnitine supplementation may improve acute exercise performance by boosting maximum oxygen consumption
These studies can guide doctors in identifying which patients might be more prone to urinary side effects
Because GLP-1s are delivered at home, they fall under pharmacy benefits but many payers only cover them for diabetes, not for weight loss